Step by Step

INTRODUCTION

4/16/2019 - Medical Grand Rounds: Bench to Bedside- Bacteriophage Therapy for Multidrug Resistant Bacterial Infections: Back to the Future

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the biological properties of bacteriophages.
  • Recognize the global challenges posed by multidrug resistant bacterial infections.
  • Describe the biology and potential therapeutic potential of bacteriophages.

Suggested Additional Reading:

Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.00954-17. doi: 10.1128/AAC.00954-17. PMC5610518

Authors:
Joseph Pilewski, MD — Associate Chief, Division of Pulmonary, Allergy & Critical Care Medicine, Associate Professor of Medicine, Cell Biology, Physiology & Pediatrics, University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.
Robert T. Schooley, MD — Professor of Medicine, Division of Infectious Diseases Vice Chair, Department of Medicine Co-Director, Center for Innovative Phage Applications and Therapeutics Senior Director, International Initiatives University of California, San Diego
Dr. Schooley receives grant/research support from Gilead Sciences, Monogram Biosciences. He is a consultant with CytoDyn and a Stockholder with Antiva Biosciences.
Authors disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded (0.1) continuing education units (CEU) which are equivalent to 1.0 contact hours.

The University of Pittsburgh is an affirmative action, equal opportunity institution.